MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer

MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer

Concomitant administration of radiotherapy with cisplatin or radiotherapy with cetuximab appear to be the treatment of choice for patients with locally advanced head and neck cancer. In the present retrospective analysis, we investigated the predictive role of several biomarkers in an unselected coh...

Full description

Bibliographic Details
Main Authors: George Fountzilas, Anna Kalogera-Fountzila, Sophia Lambaki, Ralph M. Wirtz, Angelos Nikolaou, Georgia Karayannopoulou, Mattheos Bobos, Vassiliki Kotoula, Samuel Murray, Alexandros Lambropoulos, Gerasimos Aravantinos, Konstantinos Markou, Eleni Athanassiou, Despina Misailidou, Konstantine T. Kalogeras, Demosthenis Skarlos
Format: Article
Language:English
Published: Hindawi Limited 2009-01-01
Series:Journal of Oncology
Online Access:http://dx.doi.org/10.1155/2009/305908

Internet

http://dx.doi.org/10.1155/2009/305908

Similar Items